PACTR202202745054588尚未招募未知
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 344
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 13 Year(s) 至 18 Year(s)（—）
- 性别
- All
入选标准
- •1. Patient has provided documented informed consent or assent (the informed consent form [ICF] must be reviewed and signed by each patient; in the case of adolescent patients, both the consent of the patient’s legal representative or legal guardian, and the patient’s assent must be obtained)
- •3. Patient has a confirmed diagnosis of sickle cell disease
- •Documentation of SCD genotype (HbSS, HbSß0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing; if unavailable, must be confirmed by laboratory testing during screening
- •4. Patient has had at least 2 episodes of VOC in the past 12 months
- •For study eligibility, VOC is defined as a previously documented episode of ACS or acute painful crisis (for which there was no explanation other than VOC) which required prescription or healthcare professional-instructed use of analgesics for moderate to severe pain (documentation must exist in the patient medical record prior to Screening)
- •5. Hemoglobin = 5.5 and = 10 g/dL (= 55 and = 100 g/L) during screening
- •6. For participants taking HU, the dose of HU (mg/kg) must be stable (no more than a 20% change in dosing) for at least 90 days prior to start of study treatment with no anticipated need for dose adjustments during the study, in the opinion of the Investigator
- •7. Patients, who if female and of child bearing potential, are using highly effective methods of contraception and agree not to donate ova from study start to 90 days after the last dose of study drug, and who if male are willing to use barrier methods of contraception and agree not to donate sperm, from study start to 90 days after the last dose of study drug.
排除标准
- •1. More than 10 VOCs (as defined in Inclusion Criterion 4) within the past 12 months
- •2. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the ICF
- •3. Female who is breast feeding or pregnant
- •4. Hepatic dysfunction characterized by:
- •Alanine aminotransferase (ALT) > 4.0 × upper limit of normal (ULN)
- •Direct bilirubin > 3.0 × ULN
- •5. Patients with clinically significant bacterial, fungal, parasitic, or viral infection requiring systemic therapy
- •Patients with acute bacterial, fungal, parasitic, or viral infection requiring systemic therapy should delay screening/enrollment until active therapy has been completed
- •Note: Infection prophylaxis is allowed (see concomitant medication restrictions)
- •6. Known human immunodeficiency virus (HIV) positivity
- •7. Active infection with hepatitis B virus (hepatitis B surface antigen [HepBsAg] and hepatitis B core antibody [HepBcAb] positive)
- •8. Active hepatitis C infection
- •9. Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit; calculated by the central laboratory < 30 mL/min/1.73 m2) or on chronic dialysis
- •10. History of malignancy within the past 2 years prior to treatment Day 1 requiring systemic chemotherapy and/or radiation
- •Patients with malignancy considered surgically cured are eligible (eg, non-melanoma skin cancer, cancer of the cervix in-situ, ductal carcinoma in situ [stage 1], grade 1 endometrial cancer)
- •11. History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
- •Unstable angina pectoris or myocardial infarction or elective coronary intervention
- •Congestive heart failure requiring hospitalization
- •Uncontrolled clinically significant arrhythmias
- •Symptomatic pulmonary hypertension
- •12. History of overt clinical stroke within previous 2 years or any history of an intracranial hemorrhage
- •13. Among others
研究者
相似试验
进行中（未招募）
1 期
This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years, with sickle cell disease (SCD).sickle cell disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003884-25-DEForma Therapeutics, Inc.450
进行中（未招募）
1 期
This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years, with sickle cell disease (SCD).sickle cell disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003884-25-FRForma Therapeutics, Inc.344
进行中（未招募）
1 期
This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years, with sickle cell disease (SCD).EUCTR2020-003884-25-ESForma Therapeutics, Inc.344
进行中（未招募）
1 期
This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years, with sickle cell disease (SCD).Sickle cell disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003884-25-ITFORMA THERAPEUTICS, INC.344
招募中
2 期
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell DiseaseSCDSickle Cell DiseaseLBCTR2021124934Forma Therapeutics, Inc.344